Literature DB >> 15141113

Methods for applying the quantitative structure-activity relationship paradigm.

Emilio Xavier Esposito1, Anton J Hopfinger, Jeffry D Madura.   

Abstract

There are several Quantitative Structure-Activity Relationship (QSAR) methods to assist in the design of compounds for medicinal use. Owing to the different QSAR methodologies, deciding which QSAR method to use depends on the composition of system of interest and the desired results. The relationship between a compound's binding affinity/activity to its structural properties was first noted in the 1930s by Hammett and later refined by Hansch and Fujita in the mid-1960s. In 1988 Cramer and coworkers created Comparative Molecular Field Analysis (CoMFA) incorporating the three-dimensional (3D) aspects of the compounds, specifically the electrostatic fields of the compound, into the QSAR model. Hopfinger and coworkers included an additional dimension to 3D-QSAR methodology in 1997 that eliminated the question of "Which conformation to use in a QSAR study?", creating 4D-QSAR. In 1999 Chemical Computing Group Inc. (CCG) developed the Binary-QSAR methodology and added novel 3D-QSAR descriptors to the traditional QSAR model allowing the 3D properties of compounds to be incorporated into the traditional QSAR model. Recently CCG released Probabilistic Receptor Potentials to calculate the substrate's atomic preferences in the active site. These potentials are constructed by fitting analytical functions to experimental properties of the substrates using knowledge-based methods. An overview of these and other QSAR methods will be discussed along with an in-depth examination of the methodologies used to construct QSAR models. Also, included in this chapter is a case study of molecules used to create QSAR models utilizing different methodologies and QSAR programs.

Mesh:

Year:  2004        PMID: 15141113     DOI: 10.1385/1-59259-802-1:131

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  12 in total

1.  Chemical transformations that yield compounds with distinct activity profiles.

Authors:  Ye Hu; Jürgen Bajorath
Journal:  ACS Med Chem Lett       Date:  2011-04-13       Impact factor: 4.345

Review 2.  Recent advances in fragment-based QSAR and multi-dimensional QSAR methods.

Authors:  Kyaw Zeyar Myint; Xiang-Qun Xie
Journal:  Int J Mol Sci       Date:  2010-10-08       Impact factor: 5.923

Review 3.  Applications of artificial intelligence to drug design and discovery in the big data era: a comprehensive review.

Authors:  Neetu Tripathi; Manoj Kumar Goshisht; Sanat Kumar Sahu; Charu Arora
Journal:  Mol Divers       Date:  2021-06-10       Impact factor: 2.943

Review 4.  Reviewing ligand-based rational drug design: the search for an ATP synthase inhibitor.

Authors:  Chia-Hsien Lee; Hsuan-Cheng Huang; Hsueh-Fen Juan
Journal:  Int J Mol Sci       Date:  2011-08-17       Impact factor: 5.923

5.  3D QSAR, pharmacophore and molecular docking studies of known inhibitors and designing of novel inhibitors for M18 aspartyl aminopeptidase of Plasmodium falciparum.

Authors:  Madhulata Kumari; Subhash Chandra; Neeraj Tiwari; Naidu Subbarao
Journal:  BMC Struct Biol       Date:  2016-08-17

6.  Open Source Bayesian Models. 3. Composite Models for Prediction of Binned Responses.

Authors:  Alex M Clark; Krishna Dole; Sean Ekins
Journal:  J Chem Inf Model       Date:  2016-01-19       Impact factor: 4.956

7.  wwLigCSRre: a 3D ligand-based server for hit identification and optimization.

Authors:  O Sperandio; M Petitjean; P Tuffery
Journal:  Nucleic Acids Res       Date:  2009-05-08       Impact factor: 16.971

8.  Ligand scaffold hopping combining 3D maximal substructure search and molecular similarity.

Authors:  Flavien Quintus; Olivier Sperandio; Julien Grynberg; Michel Petitjean; Pierre Tuffery
Journal:  BMC Bioinformatics       Date:  2009-08-11       Impact factor: 3.169

Review 9.  Two Decades of 4D-QSAR: A Dying Art or Staging a Comeback?

Authors:  Andrzej Bak
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

10.  A novel acylaminoimidazole derivative, WN1316, alleviates disease progression via suppression of glial inflammation in ALS mouse model.

Authors:  Kazunori Tanaka; Takuya Kanno; Yoshiko Yanagisawa; Kaori Yasutake; Satoshi Inoue; Noriaki Hirayama; Joh-E Ikeda
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.